Last reviewed · How we verify
ARM C FOLFIRI
Inhibits thymidylate synthase
Inhibits thymidylate synthase Used for Colorectal cancer.
At a glance
| Generic name | ARM C FOLFIRI |
|---|---|
| Also known as | folinic acid, fluorouracil, and irinotecan |
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | Antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Folinic acid is used to rescue the cell from the toxic effects of 5-fluorouracil. Folinic acid is a form of folic acid that is used to bypass the inhibition of thymidylate synthase.
Approved indications
- Colorectal cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Vomiting
- Neutropenia
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (PHASE1)
- Intensified Chemotherapy in CRC After Resection of Liver Metastases (PHASE2, PHASE3)
- Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer (PHASE1)
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (PHASE1)
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (PHASE3)
- A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARM C FOLFIRI CI brief — competitive landscape report
- ARM C FOLFIRI updates RSS · CI watch RSS
- GERCOR - Multidisciplinary Oncology Cooperative Group portfolio CI